Project Details
Description
Our study aims to provide preclinical proof of concept for the use psilocybin for the treatment of AD. We hypothesize that psilocybin will reduce pro-inflammatory cytokine release and increase the production of BDNF in the murine 3xTgAD model.
| Acronym | ANI409 |
|---|---|
| Status | Active |
| Effective start/end date | 1/01/25 → 31/12/27 |
Keywords
- psilocybin
- Alzheimer's disease
Flemish discipline codes in use since 2023
- Neurosciences not elsewhere classified
- Other pharmaceutical sciences not elsewhere classified
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.
Projects
- 1 Active
-
SRP85: SRP-Onderzoekszwaartepunt: Translating the biology of cognitive function to improve diagnosis and treatment of brain disorders
Smolders, I. (Administrative Promotor), De Bundel, D. (Co-Promotor), Van Eeckhaut, A. (Co-Promotor), Engelborghs, S. (Co-Promotor), Massie, A. (Co-Promotor), Nagels, G. (Co-Promotor) & Van Schependom, J. (Co-Promotor)
1/10/22 → 30/09/27
Project: Fundamental